Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial
机构:[1]Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China[2]Department of Oncology, The Affiliated Hospital of Jining Medical College, Jining, China[3]Department of Medical Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China江苏省人民医院[4]Special Needs Ward, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China[5]Department of Medical Oncology, Nantong Tumour Hospital, Nantong, China[6]Department of Medical Oncology, Northern Jiangsu People’s Hospital, Affiliated Hospital to Yangzhou University, Yangzhou, China江苏省人民医院[7]Department of Radiotherapy and Chemotherapy, Tangshan People’s Hospital, Tangshan, China[8]Department of Medical Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, China[9]Department of Oncology, Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, China[10]Department of Medical Oncology, Anhui Provincial Cancer Hospital, University of Science and Technology of China, Hefei, China[11]Department of Oncology, Fujian Provincial Hospital, Fuzhou, China[12]Department of Medical Oncology, Suining Central Hospital, Suining, China[13]Department of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China[14]Department of Thoracic Surgery Ward 2, Yunnan Cancer Hospital, Kunming, China[15]Department of Medical Oncology, Henan Tumour Hospital, Zhengzhou, China河南省肿瘤医院[16]Department of Thoracic Tumour Radiotherapy Ward 2, Jiangxi Cancer Hospital, Nanchang, China[17]Department of Medical Oncology, Inner Mongolia People’s Hospital, Hohhot, China[18]Department of Digestive Oncology Ward 2, Harbin Medical University Cancer Hospital, Harbin, China[19]Department of Medical Oncology, Puyang Oilfield General Hospital, Puyang, China[20]Department of Medical Oncology Three, Handan Central Hospital, Handan, China[21]Department of Oncology, Qilu Hospital of Shandong University, Jinan, China[22]Oncology Department, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China[23]Department of Tumour Chemotherapy, Anhui Provincial Hospital, Hefei, China[24][24][25]Department of Medical Oncology, Centre François Baclesse, Caen, France[26][26][27]Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris, France[28]Medical Science and Strategy Oncology, Innovent Biologics, China[29]Department of Statistics, Innovent Biologics, China[30]Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China
第一作者机构:[1]Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China
通讯作者:
推荐引用方式(GB/T 7714):
Lu Zhihao,Wang Junye,Shu Yongqian,et al.Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial[J].BMJ (Clinical research ed.).2022,377:e068714.doi:10.1136/bmj-2021-068714.
APA:
Lu Zhihao,Wang Junye,Shu Yongqian,Liu Lianke,Kong Li...&Shen Lin.(2022).Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.BMJ (Clinical research ed.),377,
MLA:
Lu Zhihao,et al."Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial".BMJ (Clinical research ed.) 377.(2022):e068714